Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$0.25
EPS est.
$0.18
EPS surprise
+38.89%
1-day move
-6.80%
—
Est. EPS
$0.67
Est. Rev
$390M
Impl. Move
±4.5%
Aurinia Pharmaceuticals reported an EPS of $0.25, exceeding expectations significantly. However, the stock fell by 6.8% in reaction to the earnings report. The lack of revenue data and management commentary may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.25 | N/A | +38.89% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.